CNW/ - Pharmascience Canada is proud to announce the launch of  Pr  pms-RUPATADINE (rupatadine), a treatment that helps relieve nasal and non-nasal ...

Specifically, the FDA approved Omvoh to treat moderately to severely ... first anti-amyloid therapy to offer at-home maintenance dosing. The recommendation covers Lynparza’s use in patients ...

Oral IL-23-directed alternatives are starting to filter through the industry pipeline that aim to offer more convenient dosing to the injectables, including J&J's JNJ-2113, which has already ...

Dosing a statin (rosuvastatin) every other day (EOD) may provide significant lipoprotein changes while avoiding common adverse effects in this statin-intolerant population. Objective: To determine ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes after two years of continuous treatment with Omvoh ...

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...

as well as the approval of Omvoh for moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY) has seen impressive growth in recent years, largely due to the success of its ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...